Legal & General Group PLC Cti Biopharma Corp Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.08 - $9.1 $139,454 - $311,038	-34,180 Reduced 78.54%	9,340 $84,000
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $41,533 - $59,432	9,889 Added 29.4%	43,520 $182,000
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $106,194 - $147,240	23,864 Added 244.33%	33,631 $202,000
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $8,168 - $11,323	1,524 Added 18.49%	9,767 $57,000
Q2 2022 Aug 22, 2022	BUY	$3.55 - $6.27 $29,262 - $51,683	8,243 New	8,243 $49,000
Q3 2019 Nov 13, 2019	SELL	$0.64 - $0.92 $4,864 - $6,992	-7,601 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$3.81 - $5.26 $28,959 - $39,981	7,601 New	7,601 $38,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.